The use of computer models in pharmaceutical safety evaluation

ATLA Alternatives to Laboratory Animals

Volumn 37, Issue 5, 2009, Pages 467-475

  Boyer, Scott ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Drug toxicity; In silico; Off target pharmacology; Organ toxicity; Pharmacophore; QSAR

Indexed keywords

POTASSIUM CHANNEL HERG; DRUG;

AMES TEST; COMPUTER MODEL; DATA BASE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; INFORMATION SCIENCE; LIPID SOLUBILITY; LIPIDOSIS; LIVER TOXICITY; MOLECULAR MODEL; PHARMACOPHORE; POLYPHARMACY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QT PROLONGATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TOXICOKINETICS; ANIMAL TESTING ALTERNATIVE; BIOLOGICAL MODEL; CHEMISTRY; HUMAN; METHODOLOGY; TOXICITY TESTING; TOXICOLOGY;

ANIMAL TESTING ALTERNATIVES; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS; TOXICOLOGY;

EID: 77949898228     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119290903700505     Document Type: Review

References (70)

1. NLM Bibliographic Services Division (2009). Author Counts. Available at: www.nlm.nih.gov/bsd/stats/author-counts.xls (Accessed 29.09.09). Bethesda, MD, USA: United States National Library of Medicine, National Institutes of Health.
2. Johns Hopkins University (undated). OMIM® - Online Mendelian Inheritance in Man. Available at: www.ncbi.nlm.nih.gov/omim (Accessed 29.09.09). Bethesda, MD, USA: National Center for Biotechnology Information, United States National Library of Medicine; Baltimore, MD, USA: McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine.
3. The Jackson Laboratory (undated). MGI: Mouse Genome Informatics. Available at: www.informatics.jax.org (Accessed 29.09.09). Bar Harbor, ME, USA: The Jackson Laboratory.
4. Buckley, L.A. & Dorato, M.A. (2009). High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective. Regulatory Pharmacology & Toxicology 54, 301-307.
5. Crum-Brown, A. & Fraser, T.R. (1868-1869). On the correlation between chemical consitution and physiological action: Part 1. On the physiological action of the salts of the ammonium bases derived from Strychnia, Brusia, Thebia, Codea, Morpia and Nicotia. Transactions of the Royal Society Edinburgh 25, 151-203.
6. Richet, M.C. (1893). Noté sur le rapport entre la toxicité et les proprirétés physiques des corps. Comptes-Rendus de la Société de Biologie (Paris) 45, 775-776.
7. Kubinyi, H. (2002). From narcosis to hyperspace: The history of QSAR. Quantitative Structure-Activity Relationships 21, 348-356.
8. Hansch, C. (1969). A quantitative approach to biological structure-activity relationships. Accounts of Chemical Research 2, 232-239.
9. Ames, B.N., Gurney, E.G., Miller, J.A. & Bartsch, H. (1972). Carcinogens as frameshift mutagens: Metabolites and derivatives of 2-acetylaminofluorene and other aromatic amine carcinogens. Proceedings of the National Academy of Sciences of the USA 69, 3128-12132
10. Ashby, J. (1985). Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity. Environmental Mutagenesis 7, 919-922.
11. Ashby, J. & Tennant, R.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US NTP. Mutation Research 257, 229-306.
12. Kazius, J., McGuire, R. & Bursi, R. (2005). Derivation and validation of toxicphores for mutagenicity prediction. Journal of Medicinal Chemisty 48, 312-320. (Pubitemid 40105270)
13. Benigni, R. (2005). Structure-activity relationship studies of chemical mutagens and carcinogens: Mechanistic investigation and prediction approaches. Chemical Reviews 105, 1767-1800.
14. Hatch, F.T., Knize, M.G. & Colvin, M.E. (2001). Extended quantitative structure-activity relationships for 80 aromatic and heterocyclic amines: Structural, electronic, hydropathic factors affecting mutagenic potency. Environmental & Molecular Mutagenesis 38, 268-291.
15. Judson, P.N. (1994). Rule induction for systems predicting biological activity. Journal of Chemical Information & Computer Sciences 34, 148-153.
16. Klopman, G. (1992). Multi-CASE: A hierarchical computer automated structure evaluation program. Quantitative Structure-Activity Relationships 11, 172-184.
17. Richard, A.M., & Williams, C.R. (2003). Public sources of mutagenicity and carcinogenicity data: Use in structure-activity relationship models. In Quantitative Structure-Activity Relationship (QSAR) Models of Mutagens and Carcinogens (ed. R. Benigni), pp. 145-174. Boca Raton, FL, USA: CRC Press LLC.
18. Yang, C., Hasselgren, C.H., Boyer, S., Arvidson, K., Aveston, S., Dierkes, P., Benigni, R., Benz, R.D., Contrera, J., Kruhlak, N.L., Matthews, E.J., Han, X., Jaworska, J., Kemper, R.A., Rathman, J.F. & Richard, A.M. (2008). Understanding genetic toxicology through data mining: The process of building knowledge by integrating multiple genetic toxicity databases. Toxicology Mechanisms & Methods 18, 277-295.
19. Snyder, R.D. (2009). An update on the genetoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity. Environmental & Molecular Mutagenesis 50, 435-450.
20. Carlsson, L.A., Ahlberg Helgee, E. & Boyer, S. (2009). Interpretation of non-linear QSAR models applied to Ames mutagenicity data. Journal of Chemical Information & Modeling, in press.
21. Kola, I. (2008). The state of innovation in drug development. Clinical Pharmacology & Therapeutics 83, 227-230.
22. Arrigoni, C. & Crivori, P. (2007). Assessment of QT liabilities in drug development. Cell & Biological Toxicology 23, 1-13.
23. ICH (2000). ICH Harmonised Tripartite Guideline. S7A: Safety Pharmacology Studies for Human Pharmaceuticals. CPMP/ICH/539/00, 13pp. Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).
24. ICH (2005). ICH Harmonised Tripartite Guideline. S7B: The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. CPMP/ICH/423/02, 14pp. Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).
25. ICH (2005). ICH Harmonised Tripartite Guideline. E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrythmic Potential for Non-antiarrythmic Drugs. CHMP/ICH/2/04, 18pp. Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).
26. + conduction and selectivity. Science, New York 280, 69.
27. Sanguinetti, M.C. & Tristani-Firouzi, M. (2006). hERG potassium channels and cardiac arrhythmia. Nature, London 440, 463-469.
28. Perry, M., Stansfeld, P.J., Leaney, J., Wood, C., de Groot, M.J., Leishman, D., Sutcliff, M. & Mitcheson, J.S. (2006). Drug binding interactions in the inner cavity of the hERG channels: Molecule insights from structure-activity relationships of clofilium and ibutilide analogs. Molecular Pharmacology 69, 509-519.
29. + channel blockers. Journal of Medicinal Chemistry 45, 3844-3853.
30. Ekins, S., Crumb, W.J., Sarazan, R.D., Wikel, J.H. & Wrighton, S.A. (2002). Three-dimentional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. Journal of Pharmacology & Experimental Therapeutics 301, 427-437.
31. Pearlstein, R.A., Vaz, R.J., Kang, J., Chen, X.L., Preobrazhenskaya, M., Shchekotikhin, A.E., Korolev, A.M., Lysenkova, L.N., Miroshnikova, O.V., Hendrix, J. & Rampe, D. (2003). Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorganic & Medicinal Chemistry Letters 13, 1828-1835.
32. Aronov, A.M. (2005). Predictive in silico modeling for hERG channel blockers. Drug Discovery Today 10, 149-155. (Pubitemid 40247813)
33. Roche, O., Trube, G., Zuegge, J., Pflimlin, P., Alanine, A. & Schneider, G. (2002). A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Chembiochem 3, 455-459.
34. Gavaghan, C.L., Hasselgren Arnby, C., Blomberg, N., Strandlund, G. & Boyer, S. (2007). Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. Journal of Computer-aided Molecular Design 21, 189-206. (Pubitemid 46510843)
35. Tetko, I.V. (2002). Neural network studies. 4: Introduction to associative neural networks. Journal of Chemical Information & Computer Science 42, 717-728.
36. Li, A.P. (2002). A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chemico-Biological Interactions 142, 7-23.
37. Peters, J.U., Hunziker, D., Fischer, H., Kansy, M., Weber, S., Kritter, S., Müller, A., Wallier, A., Ricklin, F., Boehringer, M., Poli, S.M., Csato, M. & Loeffler, B-M. (2004). An aminomethylpyrimidine DPP-IV inhibitor with improved properties. Bioorganic & Medicinal Chemistry Letters 14, 3575-3578.
38. Pelletier, D.J., Gehlhaar, D., Tilloy-Ellul, A., Johnson, T.O. & Greene, N. (2007). Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. Journal of Chemical Information & Modeling 47, 1196-1205. (Pubitemid 46973733)
39. Chandra, P. & Brouwer, K.L.R. (2004). The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharmaceutical Research 21, 719-735.
40. Ecker, G.F., Stockner, T. & Chiba, P. (2008). Computational models for prediction of interactions with ABC-transporters. Drug Discovery Today 13, 311-317.
41. Baillie, T.A. & Kassahun, K. (2001). Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry. Advances in Experimental Medicine & Biology 500, 45-51.
42. Uetrecht, J.P. (2000). Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Current Drug Metabolism 1, 133-141.
43. Kalgutkar, A.S., Gardner, I., Obach, R.S., Shaffer, C.L., Callegari, E., Henne, K.R., Mutlib, A.E., Dalvie, D.K., Lee, J.S., Nakai, Y., O'Donnell, J.P., Boer, J. & Harriman, S.P. (2005). A comprehensive listing of bioactivation pathways of organic functional groups. Current Drug Metabolism 6, 161-225.
44. Barone, L., Boyer, S., Damewood, J., Fikes, J., Matis, S., Gibson, G. & Ciaccio, P. (2009). Are phospholipogenic compounds associated with more toxicities than non-phospholipogenic compounds? 48th Annual Meeting of the Society of Toxicology, Baltimore, MD, USA, 15-19 March, 2009. Abstract No.2066 The Toxicologist, in press.
45. Afzelius, L., Hasselgren Arnby, C., Broo, A., Carlsson, L., Isaksson, C., Jurva, U., Kjellander, B., Kolmodin, K., Nilsson, K., Raubacher, F. & Weidolf, L. (2007). State-of-the-art tools for computational site of metabolism predictions: Comparative analysis, mechanistical insights, and future applications. Drug Metabolism Reviews 39, 61-86. (Pubitemid 46263530)
46. Corley, R.A., Minard, K.R., Kabilan, S., Einstein, D.R., Kuprat, A.P., Harkema, J.R., Kimbell, J., Gargas, M.L. & Kinzell, J.H. (2009). Magnetic resonance imaging and computational fluid dynamics (CFD) simulations of rabbit nasal airflows for the development of hybrid CFD/PBPK models. Inhalation Toxicology 21, 512-518.
47. Anon. (2008). The Virtual Liver Project: Simulating Tissue Injury Through Molecular and Cellular Processes. Available at: http://cfpub.epa.gov/ncea/cfm/ recordisplay.cfm?deid=198131 (Accessed 30.09.09). Washington, DC, USA: National Center for Environmental Assessment, US Environmental Protection Agency.
48. Noble, D. (2007). From the Hodgkin-Huxley axon to the virtual heart. Journal of Physiology 580, 15-22.
49. Anon. (2009). Home page of the Virtual Physiological Human Network of Excellence (VPH NoE) and information portal for the VPH Initiative. Available at: http://www.vph-noe.eu (Accessed 30.09.09). Brussels, Belgium: European Commission 7th Framework Programme.
50. Fliri, A.F., Loging, W.T., Thadeio, P.F. & Volkman, R.A. (2005). Biological spectra analysis: Linking biological activity profiles to molecular structure. Proceedings of the National Academy of Sciences of the USA 102, 261-266. (Pubitemid 40116755)
51. Fliri, A.F., Loging, W.T., Thadeio, P.F. & Volkman, R.A. (2005). Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nature Chemical Biology 1, 389-397.
52. Bender, A., Schreiber, J., Glick, M., Davies, J.W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S. & Jenkins, J.L. (2007). Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2, 861-873.
53. Mestres, J., Martín-Couce, L., Gregori-Puigjané, E., Cases, M. & Boyer, S. (2006). Ligand-based approach to in silico pharmacology: Nuclear receptor profiling. Journal of Chemical Information & Modeling 46, 2725-2736. (Pubitemid 46008141)
54. Bonachéra, F., Parent, B., Barbosa, F., Froloff, N. & Horvath, D. (2006). Fuzzy tricentric pharmacophore fingerprints. 1: Topological fuzzy pharmacophore triplets and adapted molecular similarity scoring schemes. Journal of Chemical Information & Modeling 46, 2457-2477. (Pubitemid 46008118)
55. Schreiber, J., Jenkins, J.L., Sukuru, S.C., Bender, A., Mikhailov, D., Milik, M., Azzaoui, K., Whitebread, S., Hamon, J., Urban, L., Glick, M. & Davies, J.W. (2009). Mapping adverse drug reactions in chemical space. Journal of Medicinal Chemistry 52, 3103-3107.
56. Keiser, M.J., Roth, B.L., Armbruster, B.N., Ernsberger, P., Irwin, J.J. & Shoichet, B.K. (2007). Relating protein pharmacology by ligand chemistry. Nature Biotechnology 25, 197-206.
57. Anon. (undated). The PubChem Project. Available at: http://pubchem.ncbi. nlm.nih.gov (Accessed 30.09.09). Bethesda, MD, USA: National Center for Biotechnology Information, United States National Library of Medicine.
58. Anon. (undated). Contract Research Organisations (CROs) from India: GVK-BIO. Available at: http://www.gvkbio.com (Accessed 30.09.09). Hyderabad, India: GVK Biosciences Private Limited.
59. Anon. (undated). Contract Research Organisations (CROs). Available at: http://www.cerep.fr/cerep/users/pages/collaborations/bioprint.asp (Accessed 20.09.09). Paris, France: Cerep.
60. Olah, M., Mracec, M., Ostopovici, L., Rad, R., Bora, A., Hadarugan N., Olah, I., Banda, M., Simon, Z., Mracec, M. & Oprea, T.I. (2004). WOMBAT: World of Molecular Bioactivity, In Chemoinformatics in Drug Discovery (ed. T.I. Oprea), pp. 223-239. New York, NY, USA: Wiley-VCH.
61. Boström, J., Hogner, A. & Schmitt, S. (2006). Do similar ligands bind in a similar fashion? Journal of Medicinal Chemistry 49, 6716-6725.
62. Friesner, R.A. & Guallar, V. (2005). Ab initio quantum chemical and mixed quantum mechanics/molecular mechanics (QM/MM) methods for studying enzymatic catalysis. Annual Review of Physical Chemistry 56, 389-427.
63. Leeson, P.D. & Springthorpe, B. (2007). The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Reviews Drug Discovery 6, 881-890.
64. Hughes, J.D., Blagg, J., Price, D.A., Bailey, S., DeCrescenzo, G.A., Devraj, R.V., Ellsworth, E., Fobian, Y.M., Gibbs, M.E., Gilles, R.W., Greene, N., Huang, E., Krieger-Burke, T., Loesel, J., Wager, T., Whiteley, L. & Zhang, Y. (2008). Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorganic & Medicinal Chemistry Letters 18, 4872-4875.
65. Rees, D.C., Congreve, M., Murray, C.W. & Carr, R. (2004). Fragment-based lead discovery. Nature Reviews Drug Discovery 3, 660-672.
66. Roth, B.L., Sheffer, D.J. & Kroeze, W.K. (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews Drug Discovery 3, 353-359.
67. Anon. (undated). EU-ADR website. Available at: www.alert-project.org (Accessed 30.09.09). Brussels, Belgium: European Commission 7th Framework Programme.
68. Ingenuity Systems (2009). Ingenuity Pathway Analysis Software - Complete Pathways Database. Available at: http://www.ingenuity.com (Accessed 30.09.09). Redwood City, CA, USA: Ingenuity Systems, Inc.
69. GeneGo (2009). GeneGO: Bioinformatics Software for Systems Biology & Drug Discovery. Available at: http://www.genego.com (Accessed 30.09.09). St Joseph, MI, USA: GeneGo Bioinformatics Software, Inc.
70. Ariadne (2009). Pathway Studio®: Software for Visualization and Analysis of Biological Pathways. Available at: http://www.ariadnegenomics.com/ products/pathway-studio (Accessed 30.09.09). Rockville, MD, USA: Ariadne, Inc.